Search Within

Genitourinary Oncology Service

  1. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Journal Article (274)
  2. Meeting Abstract (203)
  3. Conference Paper (5)
  4. Review (4)
  5. Book Section (3)
  6. Book Whole (1)
Groups
  1. Department of Medicine (490)
  2. Molecular Pharmacology and Chemistry Program Faculty (490)
  3. Sloan Kettering Institute Faculty (490)
  4. Solid Tumor Oncology Division (490)
  5. GSK Faculty (437)
  6. Radiology, Department of (206)

More Groups

People
  1. Howard Scher (229)
  2. Neal Rosen (182)
  3. David Solit (171)
  4. Steven Larson (151)
  5. Michael Morris (110)
  6. Jason Koutcher (74)

More People

Years
  1. 2025 (2)
  2. 2024 (2)
  3. 2023 (3)
  4. 2022 (8)
  5. 2021 (9)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (78)
  2. Cancer Research (69)
  3. Clinical Cancer Research (45)
  4. Journal of Nuclear Medicine (36)
  5. Proceedings of the American Association for Cancer Research Annual Meeting (27)
  6. Cancer Discovery (13)

More Publications

Publishers
  1. American Association for Cancer Research (158)
  2. American Society of Clinical Oncology (80)
  3. Society of Nuclear Medicine (36)
  4. Nature Publishing Group (31)
  5. Elsevier Inc. (26)
  6. Wiley Blackwell (18)

More Publishers

Results (490)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy
    Meeting Abstract

    Morris, M. J.; Flynn, J.; Zhao, B.; Anand, A.; Sjöstrand, K.; Larson, S. M.; Scher, H. I.; Regazzi, A. M.; Borzillo, G. V.; Park, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients
    Meeting Abstract

    Knezevic, A.; Heller, G.; Sjöstrand, K.; Anand, A.; Borzillo, G.; Larson, S.; Morris, M. J.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • BRAF — A tumour-agnostic drug target with lineage-specific dependencies
    Review

    Hanrahan, A. J.; Chen, Z.; Rosen, N.; Solit, D. B.
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Impact of tumor metabolism on the microenvironment and response to immunotherapy
    Meeting Abstract

    Zappasodi, R.; Serganova, I.; Brunschvig, S.; Santhella, A.; Mane, M.; Vemuri, K.; Ijoma, J.; Kang, W.; Manovatodorova, K.; Koutcher, J.; more...
    Cancer Science (2023)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Molecular characterization of acquired resistance to KRAS(G12C)–EGFR inhibition in colorectal cancer
    Journal Article

    Yaeger, R.; Mezzadra, R.; Sinopoli, J.; Bian, Y.; Marasco, M.; Kaplun, E.; Gao, H.; Zhao, H. Y.; Paula, A. D. C.; Zhu, Y.; more...
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Deferiprone alters macrophage function and metabolism
    Meeting Abstract

    Ackerstaff, E.; Budhu, S.; Winkleman, D. P.; Min, S. S.; Ijoma, J. N.; Serganova, I. S.; Blasberg, R. G.; Merghoub, T.; Koutcher, J. A.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • RAF-Independent MEK mutations drive histiocytic neoplasms in vivo and are sensitive to single-agent ERK inhibition in patients
    Meeting Abstract

    Durham, B. H.; Singer, M. E.; Benbarche, S.; Erickson, C.; Rahman, J.; Solit, D. B.; Witkowski, M.; Rosen, N.; Abdel-Wahab, O.; Diamond, E. L.
    Blood (2022)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save